Citigroup
CRDF icon

Citigroup’s Cardiff Oncology CRDF Stock Holding History

Citigroup’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-40
Closed -$2K – 7560
2017
Q3 		$2K Sell
40
-25
-38% -$1.56K ﹤0.01% 7013
2017
Q2 		$6K Buy
+65
New +$4.19K ﹤0.01% 6681

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citigroup's CRDF Position: Q2 2026 in Review

Citigroup reduced its Cardiff Oncology (CRDF) stake by 99% in Q2 2026, selling an estimated $63.1K and leaving 501 shares worth $651. The position accounts for ﹤0.01% of the portfolio, ranked #5444.

Citigroup first reported a position in CRDF in Q2 2013 and has held it in 38 quarters since. The position peaked at $1.07M in Q1 2023. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • Citigroup held 501 shares of Cardiff Oncology worth $651 as of Q2 2026.
  • Citigroup sold 39,765 Cardiff Oncology shares in Q2 2026, an estimated $63.1K.
  • Cardiff Oncology made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5444 holding.
  • Citigroup first reported a position in Cardiff Oncology in Q2 2013 and has held it in 38 quarters since.
  • Citigroup's Cardiff Oncology position peaked at $1.07M in Q1 2023.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.